What are the exclusion criteria for trimodality treatment (maximal transurethral resection followed by concurrent chemoradiation) in patients with muscle‑invasive bladder cancer?

Exclusion Criteria for Trimodality Treatment in MIBC

While there are no absolute contraindications to trimodality therapy (TMT) for muscle-invasive bladder cancer, poor prognostic factors that should prompt careful consideration include multifocal tumors, advanced stage (cT3-4a), hydronephrosis, multifocal carcinoma in situ (CIS), and poor baseline bladder function. 1

Relative Exclusion Criteria (Poor Prognostic Factors)

The 2026 International Bladder Cancer Group guidelines emphasize that ideal candidates for TMT have unifocal cT2 disease without hydronephrosis or concomitant multifocal CIS, with good baseline bladder function 1. However, the guidelines explicitly state that cT3-4a stage, hydronephrosis, and CIS are poor prognostic factors but NOT absolute contraindications to TMT 1.

Tumor-Related Factors:

• Multifocal disease - associated with worse outcomes but not an absolute exclusion
• Advanced local stage (cT3-4a) - poor prognostic factor; consider induction systemic chemotherapy before TMT 1
• Hydronephrosis - poor prognostic factor; consider induction chemotherapy 1
• Multifocal carcinoma in situ - unfavorable but not absolute contraindication 1
• Inability to achieve maximal TURBT - compromises outcomes 2, 3

Patient-Related Factors:

• Poor baseline bladder function - critical exclusion as bladder preservation is the goal 1
• ECOG performance status >2 - limits ability to tolerate treatment 2
• Inability to comply with intensive surveillance - essential for detecting recurrence 4

Histologic Considerations

Variant histologies are NOT exclusions for TMT. Recent data show no significant differences in outcomes between pure urothelial carcinoma and histologic subtypes after TMT 1. However, pure squamous-cell carcinoma or adenocarcinoma are best managed with upfront radical cystectomy rather than TMT 5.

Important exception: Small cell variants should be excluded from TMT 2.

Nodal Disease

Limited nodal disease (cN1) is not an absolute contraindication but requires induction systemic chemotherapy (strongly recommended) 1. Patients with cN+ disease in the pelvis should receive cisplatin-based chemotherapy prior to radiation with concurrent radiosensitizer 1.

Critical Pitfalls to Avoid

1. Do not exclude patients solely based on cT3-4a stage, hydronephrosis, or CIS - these were historically considered contraindications but contemporary evidence shows TMT can still be effective with appropriate patient selection and intensified treatment 1

2. Do not proceed with TMT if maximal TURBT cannot be achieved - incomplete resection significantly compromises outcomes 3, 6

3. Do not offer TMT to patients with poor bladder function - defeats the purpose of bladder preservation 1

4. Ensure multidisciplinary evaluation - all MIBC patients should be evaluated by urologic oncology, medical oncology, and radiation oncology before deciding on TMT 1

Practical Algorithm for Patient Selection

Step 1: Confirm muscle-invasive disease with expert genitourinary pathology review 1

Step 2: Assess tumor characteristics:

• Unifocal cT2 without hydronephrosis or multifocal CIS = ideal candidate
• Multifocal, cT3-4a, hydronephrosis, or CIS = consider but add induction chemotherapy 1
• Pure squamous or adenocarcinoma = recommend radical cystectomy instead 5

Step 3: Evaluate patient factors:

• Good bladder function + ECOG 0-2 + ability to comply with surveillance = proceed
• Poor bladder function or inability to comply = consider radical cystectomy

Step 4: Ensure maximal safe TURBT can be performed 1, 2